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Background: Registries of pancreatic surgery have become increasingly popular as they facilitate both
quality improvement and clinical research. We aimed to compare registries for design, variables
collected, patient characteristics, treatment strategies, clinical outcomes, and pathology.
Methods: Registered variables and outcomes of pancreatoduodenectomy (2014e2017) in 4 nationwide or
multicenter pancreatic surgery registries from the United States of America (American College of Sur-
geons National Surgical Quality Improvement Program), Germany (Deutsche Gesellschaft für Allgemein-
und Viszeralchirurgie - Studien-, Dokumentations- und Qualit€atszentrum), the Netherlands (Dutch
Pancreatic Cancer Audit), and Sweden (Swedish National Pancreatic and Periampullary Cancer Registry)
were compared. A core registry set of 55 parameters was identified and evaluated using relative and
absolute largest differences between extremes (smallest versus largest).
Results: Overall, 22,983 pancreatoduodenectomies were included (15,224, 3,558, 2,795, and 1,406 in the
United States of America, Germany, the Netherlands, and Sweden). Design of the registries varied
because 20 out of 55 (36.4%) core parameters were not available in 1 or more registries. Preoperative
chemotherapy in patients with pancreatic ductal adenocarcinoma was administered in 27.6%, 4.9%, 7.0%,
and 3.4% (relative largest difference 8.1, absolute largest difference 24.2%, P < .001). Minimally invasive
surgery was performed in 7.8%, 4.5%, 13.5%, and unknown (relative largest difference 3.0, absolute largest
difference 9.0%, P < .001). Median length of stay was 8.0, 16.0, 12.0, and 11.0 days (relative largest dif-
ference 2.0, absolute largest difference 8.0, P < .001). Reoperation was performed in 5.7%, 17.1%, 8.7%, andD, Department of Surgery,
sity of Amsterdam, Meiberg-
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Tara.M. Mackay et al. / Surgery xxx (2020) 1e7211.2% (relative largest difference 3.0, absolute largest difference 11.4%, P < .001). In-hospital mortality was
1.3%, 4.7%, 3.6%, and 2.7% (relative largest difference 3.6, absolute largest difference 3.4%, P < .001).
Conclusion: Considerable differences exist in the design, variables, patients, treatment strategies, and
outcomes in 4 Western registries of pancreatic surgery. The absolute largest differences of 24.3% for the
use of preoperative chemotherapy, 9.0% for minimally invasive surgery, 11.4% for reoperation rate, and
3.4% for in-hospital mortality require further study and improvement. This analysis provides 55 core
parameters for pancreatic surgery registries.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
To facilitate assessment of quality and outcome of pancreatic
surgery, several nationwide and multicenter registries have been
established in recent years. Many cohort studies are performed
with registry data, which are used as the basis for daily practice,
clinical guidelines, and development of prospective studies around
the world. It is, however, unclear to what extent data from these
various registries are comparable. To ascertain adequate external
validity of reports from these registries, differences in registry
variables (eg, various variable definitions, selection of inclusion),
patient and treatment characteristics, and outcomes should not go
unnoticed.
Registry design may vary considerably. A previous European
project identified a common dataset for 11 European pancreatic
cancer registries.1 Of the 8 registries which provided data, only 3
covered surgical details of which 2 were incomplete for the shared
items in this project (eg, type of resection, vascular resection, and
postoperative complications). To provide insight in surgical practice
variation and potentially improve postoperative outcomes of
pancreatic surgery worldwide, a comparison among registries with
surgical details with a more homogenous patient group outside of
Europe is, therefore, essential.
Various Western countries have developed registries on
pancreatic surgery. Our aim was to compare differences in (1)
collected variables and definitions; (2) patient, tumor, and surgical
treatment characteristics; and (3) clinical and pathological out-
comes. Based on this comparison, a core-parameter set for regis-
tries on pancreatic surgery aimed to improve uniform data
acquisition worldwide is provided. With this effort, outcomes can
be compared more accurately, and clear benchmarks can be set
worldwide. This comparison may ultimately lead to reduced prac-
tice variation and improvement of outcomes globally.Methods
Study design
Comparison of 4 registries on pancreatic surgery with a focus on
pancreatoduodenectomy from the United States (American College
of Surgeons National Surgical Quality Improvement Program)2:
multicenter, 147 centers in 2017, including several Canadian hos-
pitals); Germany (Deutsche Gesellschaft für Allgemein- und Vis-
zeralchirurgie - Studien-, Dokumentations- und Qualit€atszentrum
[DGAV StuDoQ|Pancreas]3: multicenter, 54 centers in 2017); the
Netherlands (Dutch Pancreatic Cancer Audit [DPCA]4: nationwide,
17 centers in 2017); and Sweden (Swedish National Pancreatic and
Periampullary Cancer Registry5: nationwide, 6 centers in 2017).
Registries for pancreatic surgery from Australia, Canada, France,
Japan, and Norway were also assessed, but data were not yet suf-
ficiently available, or registries were still under construction. The
primary aim of this study was to assess the design of the registries
and, secondly, to explore the data captured in the 4 countries. We
compared differences in (1) collected variables and definitions; (2)patient, tumor, and treatment characteristics; and (3) patient out-
comes. This study was designed in accordance with the Strength-
ening the Reporting of Observational Studies in Epidemiology
guidelines.6
Study population
The study population included all adults who underwent pan-
creatoduodenectomy for all indications during a 4-year period
(2014e2017) and were registered in 1 of the 4 described registries.
Core parameters
First, a literature search was performed to identify important
risk factors and outcomes (TM), which were then discussed in the
study team. Thereafter, a panel of core parameters was established
by identifying key variables from the existing pancreatic surgery
registries by all coauthors. This effort was followed by reviewing
availability of these key variables per registry. Second, definitions of
the key variables were compared to assess whether an accurate
comparison among registries was possible. Data of all registries
were extracted by anonymized export, and the panel of core pa-
rameters from all datasets were merged for analysis. Core param-
eters were divided into baseline and preoperative characteristics,
treatment characteristics, surgical outcomes, and pathological
outcomes.
Parameter differences owing to various metric systems were
resolved by converting the data, such as weight in ounces into ki-
lograms or height in inches into meters. Several parameters were
recategorized so that data could be combined, such as functional
health status as independent, partially dependent, or totally
dependent and pancreatic duct size as 3 and >3 millimeter.
Pancreatic surgery specific complications (ie, pancreatic fistula,
postpancreatectomy hemorrhage, delayed gastric emptying, bile
leakage) were (newly) categorized according to the International
Study Group of Pancreatic Surgery and Liver Surgery criteria7e11 as
accurately as possible, as not all registries recorded these compli-
cations according to these definitions. The reoperation and read-
mission parameters differed in interval (30 days postsurgery vs 30
days postdischarge) yet were combined.
Statistical analysis
Characteristics are presented as proportions with percentages in
case of categorical data or as mean ± standard deviation or median
with interquartile ranges in case of normally or not-normally
distributed data, respectively. Statistical comparisons were done
by analysis of variance or c2 test as appropriate. Because of the large
dataset (>20,000 cases), evenminimal differences were statistically
significant; therefore, the relative and absolute largest differences
(RLD, ALD) between the smallest and largest outcomes among the 4
registries also were presented. RLD is a ratio and ALD an absolute
percentage difference. Because the primary aim was to compare
design and variables, no multivariable analysis was performed.
Fig 1. Availability of 55 core parameters during 2014 to 2017 in 4 registries on pancreatic surgery in Western countries. Diagonal stripes: available in registry. Dots: not available in
registry. COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; PD, pancreatoduodenectomy; POD, postoperative day.
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Table I




















ICU admission, n (%) NA 363 (10.2) 345 (12.3) 68 (4.8) 2.6 7.5% All patients
Missing 15 (0.4) 61 (2.2) 77 (5.5)
Surgical site infection, n (%) 1,569 (10.3) 416 (11.7) 138 (4.9) 80 (5.7) 2.4 6.8% All patients
Missing 0 (0.0) 86 (2.4) 954 (34.1) 0 (0.0)
Pneumonia, n (%) 599 (3.9) 250 (7.0) 98 (3.5) 189 (13.4) 3.8 9.9% All patients
Missing 0 (0.0) 13 (0.4) 960 (34.3) 79 (5.6)
Pancreatic fistula grade B/C, n (%) 1,658 (10.9) 490 (13.8) 394 (14.1) 222 (15.8) 1.4 4.9% All patients
Missing 140 (0.9) 15 (0.4) 23 (0.8) 1 (0.1)
Post pancreatectomy hemorrhage grade B/C, n
(%)
NA 336 (9.4) 231 (8.3) 122 (8.7) 1.1 1.1% All patients
Missing 14 (0.4) 47 (1.7) 0 (0.0)
Delayed gastric emptying grade B/C, n (%) 2,559 (16.8) 270 (10.4) 527 (18.9) 104 (7.4) 2.6 11.5% All patients
Missing 239 (1.6) 14 (0.4) 32 (1.1) 0 (0.0)
Bile leak grade B/C, n (%) NA 181 (5.1) 144 (5.2) 66 (4.7) 1.1 0.5% All patients
Missing 0 (0.0) 42 (1.5) 0 (0.0)
Radiologic intervention performed, n (%) 1,955 (12.8) NA 489 (17.5) NA 1.4 4.7% All patients
Missing 138 (0.9) 86 (3.1)
Organ failure, n (%) 927 (6.1) 363 (10.2) 209 (7.5) 68 (4.8) 2.1 5.4% All patients
Missing 0 (0.0) 15 (0.4) 122 (4.4) 77 (5.5)
Reoperation, n (%) 866 (5.7) 607 (17.1) 242 (8.7) 157 (11.2) 3.0 11.4% All patients
Missing 0 (0.0) 35 (1.0) 98 (3.5) 79 (5.6)
Length of stay, median days (IQR) 8.0 (6.0e12.0) 16.0 (13.0e24.0) 12.0 (8.0e19.0) 11.0 (8.0e17.0) 2.0 8.0 Excluding patients
with in-hospital
mortality
Missing, n (%) 45/15,028 (0.3) 3/3,378 (0.1) 24/2,679 (0.9) 24/1,238 (1.9)
Readmission, n (%) 2,518 (16.5) 295 (8.3) 465 (16.6) NA 2.0 8.3% All patients
Missing 10 (0.1) 36 (1.0) 154 (5.5)
In-hospital mortality, n (%) 196 (1.3) 168 (4.7) 102 (3.6) 38 (2.7) 3.6 3.4% All patients
Missing 0 (0.0) 12 (0.3) 14 (0.5) 130 (9.2)
Clavien-Dindo classification, n (%)
No complications or Clavien Dindo <3 12,141 (79.7) 2,421 (68.0) 1,863 (66.7) 1,034 (73.5) 1.6 11.2% All patients
Clavien Dindo 3 3,083 (20.3) 1,122 (31.5) 867 (31.0) 295 (21.0)
Missing 0 (0.0) 15 (0.4) 65 (2.3) 77 (5.5)
Time between resection-death in patients with
in-hospital mortality, median days (IQR)
10.0 (6.0e16.0) 19.5 (10.0e33.8) 13.0 (6.5e25.5) 23.0 (16.5e44.5) 2.3 13 Of patients with in-
hospital mortality
Missing, n (%) 0/196 (0.0) 0/168 (0.0) 1/102 (1.0) 1/38 (2.6)
P values were all < .001.
IQR, interquartile range; NSQIP, National Surgical Quality Improvement Program; StuDoQ, Studien-, Dokumentations- und Qualit€atszentrum; DPCA, Dutch Pancreatic Cancer
Audit; SNPPCR, Swedish National Pancreatic and Periampullary Cancer Registry.
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were performed with SPSS (IBM Corporation, Armonk, NY).Results
Identified core parameters
In total, we selected 55 core parameters. Figure 1 shows the core
parameters per registry. Design of the registries varied among the
countries because 20 out of 55 (36.4%) core parameters were not
available in 1 or more registries, including pancreatic duct size,
pancreatic gland texture, abdominal drain placement during sur-
gery, intensive care unit admission, postpancreatectomy hemor-
rhage, bile leak, readmission, and resection margin (Fig 1).
For all variable definitions (including discrepancies) and details
per registry and combined variable definitions for this study, see
Supplementary Table S2. The core parameter set of 55 variables,
including detailed variable definitions, is provided in
Supplementary Table S3. Bilirubin, annual pancreatoduodenectomy
volume per center, drain fluid amylase postoperative days 1 and 3,and organ space infection were not sufficient for analyses in this
study but were included in the suggested core parameter set.Baseline and preoperative characteristics
Supplementary Table S1 demonstrates the comparison of the
core parameters among the 4 registries. Overall, 22,983 pan-
creatoduodenectomies were included (15,224 from the United
States vs 3,558 from Germany vs 2,795 from the Netherlands vs
1,406 from Sweden). Body mass index (BMI) (27.3, 25.6, 25.2, and
25.4 kg/m2, RLD 1.1, ALD 2.1) and American Society of Anesthesi-
ologists (ASA) (77.7%, 48.2%, 22.5%, and 27.2% ASA IIIeIV, RLD 3.5,
ALD 55.2%) were highest in the United States (both P < .001). Pa-
tients from the United States and Germany more often suffered
from diabetes mellitus (25.8%, 25.7%, 20.3%, and 19.7%, RLD 1.3, ALD
6.1%) and hypertension (52.9%, 56.3%, 30.3%, and 46.9%, RLD 1.9,
ALD 26.0%, both P < .001). Preoperative biliary drainage was per-
formed most often in Sweden (48.9%, 35.9%, 48.4%, and 61.0%, RLD
1.7, ALD 25.1%, P < .001). Preoperative chemotherapy in patients
with pancreatic ductal adenocarcinoma was used most often in the
Tara.M. Mackay et al. / Surgery xxx (2020) 1e7 5United States (27.6%, 4.9%, 7.0%, and 3.4%, RLD 8.1, ALD 24.2%, P <
.001).
Treatment characteristics
Laparoscopic or robotic procedures (including conversion) were
performed mostly in the Netherlands (7.8%, 4.5%, 13.5%, and un-
known, RLD 3.0, ALD 9.0%, P < .001). Pylorus preservation occurred
in 37.8%, 71.1%, 58.5%, and 23.3% (RLD 3.1, ALD 47.8%, P < .001).
Additional venous and/or arterial resection was done most
commonly in the United States and Sweden (17.2%,11.3%,14.9%, and
18.5%, RLD 1.6, ALD 7.2%, P < .001). In all countries, a pan-
creaticojejunal duct-to-mucosa anastomosis was the most frequent
type of pancreatic reconstruction (82.2%, 60.8%, 56.4%, and 51.4%,
RLD 1.6, ALD 30.8, P < .001).
Surgical outcomes
A comparison of surgical outcomes in the 4 registries is provided
in Table I. Clinically relevant pancreatic fistulae were mostly
registered in Sweden, while rates of postpancreatectomy hemor-
rhage were similar among the countries. Reoperation was
performed mostly in Germany and Sweden. Complications of
Clavien-Dindo grade 3 were reported mostly in Germany and the
Netherlands. Median length of stay was lowest in the United States,
whereas the United States and the Netherlands had the most
readmissions. In-hospital mortality was the lowest in the United
States.
Pathological outcomes
Pancreatic or periampullary (ie, duodenal, ampulla of Vater,
distal bile duct) adenocarcinomawas the indication for resection in
70.1%, 67.9%, 75.0%, and 76.9% of patients (RLD 1.1, ALD 9.0%, P <
.001). The majority of patients with pancreatic or periampullary
carcinoma had a stage T3 tumor (69.7%, 64.7%, 61.5%, and 66.6%,
RLD 1.1, ALD 8.2%, P < .001) with positive regional lymph nodes
(63.2%, 64.4%, 66.3%, and 70.6%, RLD 1.1, ALD 7.4%, P < .001). The
tumor stage was most often categorized as stage IIB (43.3%, 44.3%,
52.1%, and 57.9%, RLD 1.3, ALD 14.6%, P < .001).
Discussion
Nationwide or multicenter registries on pancreatic surgery are
becoming increasingly popular and produce large amounts of data,
which may have global clinical implications for quality control. This
first transatlantic comparison of 4 large registries from Western
countries demonstrated that over one-third of the identified 55
core parameters were not available in 1 or more registries.
Furthermore, considerable differences exist in patients and treat-
ment characteristics and outcomes. The absolute largest differences
were 6.1% for diabetes mellitus, 24.3% for the use of preoperative
chemotherapy for pancreatic cancer, 9.0% for minimally invasive
surgery, 11.4% for reoperation rate, 8 days for median length of stay,
and 3.4% for in-hospital mortality.
Interestingly, various parameters that are important predictors
of outcomes in pancreatic surgery (eg, pancreatic duct size,
pancreatic gland texture, postpancreatectomy hemorrhage, resec-
tion margin) were not registered in 1 or more registries.12,13 The
differences are partly because of the various development strate-
gies of the registries. In 2004, the American College of Surgeons
National Surgical Quality Improvement Program for pancreatic
surgery was built from the initial Veterans Affairs National Surgical
Quality Improvement Program (NSQIP), in which data on major
operations were captured with the aim to provide feedback andreduce postoperative morbidity and mortality.2 Subsequently,
members of the Americas Hepato-Pancreato-Biliary Association
Research Committee developed 24 pancreas-specific variables.
These variables were trialed at 43 institutions in 2012, made
optional for more institutions in 2013, and required at institutions
targeting pancreatectomy in 2014. The German DGAV StuDoQ|
Pancreas registry was based on guidelines and the literature, which
was reviewed by a panel of surgeons and led to national expert
consensus in 2013.3 The design of the Dutch DPCA in 2013 was
based on a systematic literature search, cross-checks with existing
registries, international consensus, and national consensus through
the Dutch Pancreatic Cancer Group.4 The Swedish registry was
developed in 2010 after literature research and consensus of a panel
of experts.5 The validity of the registries was described in previous
studies.2e5,12 The suggested core parameter set should not only be
used as a tool to develop new pancreatic surgery registries, but also
to adapt existing registries to improve worldwide uniform data
capturing and selection of patients.
For “hard” outcome parameters, such as in-hospital mortality, a
uniform definition was easily made. Many other variables could be
converted or newly categorized. For example, functional health
status was defined as the 5-tier Eastern Conference Oncology
Group 0 to 4 classification in the DPCA and Swedish registry, yet
as a 3-tier classification (independent/partially dependent/totally
dependent) in NSQIP and StuDoQ. Therefore, the combined vari-
able definition was restricted to the 3-tier classification. Another
example was the pancreatic duct size definition. In NSQIP the
lowest cutoff value was <3 millimeters, while it was 3 milli-
meters in StuDoQ. A lowest cutoff value of 3 millimeters was
chosen, which led to misclassification of several patients from
NSQIP. Although these new categories led to some information
loss or misclassification, the data still became comparable. Some
variables, however, were difficult to combine. For instance,
although ASA scores should have an unambiguous definition, the
absolute largest difference was 49% for ASA 3 classification (71% vs
22%). This large variation could point to different interpretation by
anesthesiologists or data managers or registration bias. In addi-
tion, heart failure was present in 11% in Germany and 33% in
Sweden, but 0.4% in the United States and 1% in the Netherlands.
A previous meta-analysis showed that the prevalence of all type
heart failure was 5% to 15% in older adults,14 and these rates
are expected to be lower in patients undergoing a pan-
creatoduodenectomy. The 2 higher rates are the result of ambig-
uous definitions by which other diseases (eg, rhythmic disorders)
are included in addition to heart failure, as was reported in the
data dictionaries of these registries. This finding indicates the
importance of not only implementing key parameters but also
using identical definitions in the separate registries.
Patients from the Netherlands and Sweden seem healthier than
from the United States and Germany, as they have lower BMI and
ASA scores and less diabetes mellitus and hypertension. This is
confirmed by previous studies that also demonstrated higher BMI,
diabetes, and hypertension in the US population.15 These findings
support the suggestion that patients from the Netherlands and
Sweden may be healthier as a whole. However, we cannot exclude
that selection has occurred (ie, sicker patients in the Netherlands
and Sweden not offered surgery). A second explanation for the
observed difference could be differences in patient selection be-
tween countries. For example, chronic pancreatitis was the indi-
cation for resection in 10% of the German patients compared to 3%
to 4% in the other countries. Therefore, we believe the first step is to
harmonize registries before an accurate comparison can be made.
Several interesting differences in treatment strategies were
identified among the registries. Preoperative chemo(radio)therapy
was used in 28% of patients with pancreatic adenocarcinoma in the
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countries. In many European countries, preoperative chemo(radio)
therapy is currently only administered in a study setting,16,17 which
explains these differences. For the United States, this management
strategy may explain the higher rate of hard-fibrotic pancreatic
textures (40% United States vs 31%e35% in Europe), with potentially
less pancreatic fistula (11% vs 14%e16%), and less in-hospital mor-
tality (1% vs 3%e5%).18 In addition, the presence of several very-
high-volume centers in the United States (eg, performing >300
pancreatoduodenectomies annually) may also have contributed to
the low in-hospital mortality rate.19 Unfortunately, center volume
was not available as a parameter for this study and should therefore
be taken into account in future analyses.
In Germany, the highest reoperation rate was found (17% vs
6%e11%), which is in line with a previously reported reoperation
rate of 16%.20 The reasons for reoperation were not reported.
According to a recent report, reoperation is mostly performed for
severe pancreatic fistula.21 Compared to the United States, clini-
cally relevant pancreatic fistulae were seen more often in Ger-
many (14% vs 11%). However, as the Netherlands as well as
Sweden have similar rates of pancreatic fistula as Germany (14%e
16% vs 14% in Germany), but lower reoperation rates (9%e11% vs
17% in Germany), cultural differences may have played a role. The
different reoperation rates could be related to the strategy to
treat pancreatic fistula. The United States, the Netherlands, and
Sweden may primarily treat pancreatic fistula with percutaneous
catheter drainage whereas Germany with relaparotomy. However,
this information is not recorded in the registries so this hy-
pothesis could not be tested.
Germany had the lowest readmission rate (8% vs 16%e17%).
Whereas the Netherlands used a 30-day postdischarge interval for
readmission, Germany and the United States both used a 30-day
postsurgery interval. Because the Netherlands and the United
States have similar readmission rates, the lower rate in Germany is
probably not explained by the different definitions. A systematic
review found an overall 30-day readmission rate of 17% to 21%, with
postoperative complications and severe complications as strong
predictors of readmission.22 However, (severe) postoperative
complications occurred in various rates among the countries, thus
this issue does not seem to have a direct relation with readmission
in this study. Most likely, the longer length of stay in Germany (16
vs 8e12 days) contributed to the lower readmission rate. In addi-
tion, these outcomes may be explained by factors that are difficult
to assess, such as cultural, geographical, insurance, health system
payment and reimbursement differences, and mentality toward
discharge of patients.
Some limitations of this study should be noted. First, whereas
NSQIP and StuDoQ are multicenter registries, both the DPCA and
SNPPRC are nationwide registries. In the United States and Ger-
many, this difference probably resulted in a selection and regis-
tration bias because relatively more higher-volume centers
participate in these registries. Currently in the United States,
approximately two-thirds of the pancreatectomies performed
annually are captured, and in Germany this rate is approximately
one-fifth. These varying procedures for inclusion and selection of
patients between multicenter versus nationwide registries may be
a (partial) underlying cause of several found differences. Unfortu-
nately, annual center volume for pancreatoduodenectomy was not
available in the NSQIP and Swedish audit so the extent of this dif-
ference cannot be assessed. Second, in some instances, observed
differences may be the result of definition variations among reg-
istries. This study group is now in the process of adding missing
variables and reducing variations in definition by changing these
per country according to our suggested core parameter set. Third,
all comparisons were made in the current very large dataset bywhich minimal differences were statistically significant yet were
not always clinically relevant. Fourth, some variables could not be
compared, such as drain fluid amylase. For example, some countries
may determine this at postoperative day 1, whereas others at day 3
or both days. Definitions and clinical practice were too different for
a valid comparison. In the future, consensus should be reached on
drain fluid amylase before a comparison can be made between
countries. Fifth, registries from several countries (see Methods
section) were not mature enough for inclusion or more than 50% to
75% of variables from the core parameter set was missing, and a
valid comparison was not possible. This study group aims to stay in
touch with these countries to expand their database according to
the core parameter set and possibly include them in future studies.
In conclusion, this comparison showed that even in 4 Western
countries the design of 4 pancreatic surgery registries differs.
Furthermore, differences in patient selection and characteristics,
treatment strategies, and outcomes exist, which requires further
study and improvement. Harmonizing registries provides an op-
portunity to compare outcomes accurately, set clean benchmarks,
and combine and extrapolate data from different countries. Ulti-
mately, reducing practice variation may improve outcomes
globally.
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